Patents by Inventor Aamir Mir

Aamir Mir has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Engineered enzymes
    Patent number: 10876102
    Abstract: The present disclosure provides engineered RNA-guided enzymes for editing live cells.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: December 29, 2020
    Assignee: Inscripta, Inc.
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Kyle Seamon, Andrew Garst
  • Nucleic acid-guided nucleases
    Patent number: 10870841
    Abstract: The present disclosure provides novel RNA-guided enzymes for making rational and direct edits to the genome of live cells.
    Type: Grant
    Filed: August 9, 2020
    Date of Patent: December 22, 2020
    Assignee: Inscripta, Inc.
    Inventors: Benjamin Mijts, Aamir Mir, Andrew Garst, Juhan Kim, Kyle Seamon
  • ENGINEERED ENZYMES
    Publication number: 20200354703
    Abstract: The present disclosure provides engineered RNA-guided enzymes for editing live cells.
    Type: Application
    Filed: April 9, 2020
    Publication date: November 12, 2020
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Kyle Seamon, Andrew Garst
  • Nucleic acid-guided nucleases
    Patent number: 10767169
    Abstract: The present disclosure provides novel RNA-guided enzymes for making rational and direct edits to the genome of live cells.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: September 8, 2020
    Assignee: Inscripta, Inc.
    Inventors: Juhan Kim, Benjamin Mijts, Aamir Mir, Andrew Garst, Kyle Seamon
  • Nucleic acid-guided nucleases
    Patent number: 10745678
    Abstract: The present disclosure provides novel RNA-guided enzymes for making rational and direct edits to the genome of live cells.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: August 18, 2020
    Assignee: Inscripta, Inc.
    Inventors: Juhan Kim, Benjamin Mijts, Aamir Mir, Andrew Garst, Kyle Seamon
  • Nucleic acid-guided nucleases
    Patent number: 10724021
    Abstract: The present disclosure provides novel RNA-guided enzymes for making rational and direct edits to the genome of live cells.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: July 28, 2020
    Assignee: Inscripta, Inc.
    Inventors: Juhan Kim, Benjamin Mijts, Aamir Mir, Andrew Garst, Kyle Seamon
  • Nucleic acid-guided nucleases
    Patent number: 10704033
    Abstract: The present disclosure provides novel RNA-guided enzymes for making rational and direct edits to the genome of live cells.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: July 7, 2020
    Assignee: Inscripta, Inc.
    Inventors: Juhan Kim, Benjamin Mijts, Aamir Mir, Andrew Garst, Kyle Seamon
  • Automated multi-module cell processing methods, instruments, and systems
    Patent number: 10689669
    Abstract: The present disclosure provides automated multi-module instruments, compositions and methods to increase the percentage of edited mammalian cells in a cell population when employing nucleic-acid guided editing.
    Type: Grant
    Filed: January 11, 2020
    Date of Patent: June 23, 2020
    Assignee: Inscripta, Inc.
    Inventors: Emily Feldman, Benjamin Mijts, Aamir Mir, Erik Zimmerman, Andrew Garst
  • ENGINEERED ENZYMES
    Publication number: 20200181592
    Abstract: The present disclosure provides engineered RNA-guided enzymes for editing live cells.
    Type: Application
    Filed: February 22, 2020
    Publication date: June 11, 2020
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Kyle Seamon, Andrew Garst
  • Engineered enzymes
    Patent number: 10655114
    Abstract: The present disclosure provides engineered RNA-guided enzymes for editing live cells.
    Type: Grant
    Filed: February 22, 2020
    Date of Patent: May 19, 2020
    Assignee: Inscripta, Inc.
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Kyle Seamon, Andrew Garst
  • Engineered enzymes
    Patent number: 10640754
    Abstract: The present disclosure provides engineered RNA-guided enzymes for editing live cells.
    Type: Grant
    Filed: February 22, 2020
    Date of Patent: May 5, 2020
    Assignee: Inscripta, Inc.
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Kyle Seamon, Andrew Garst
  • ENGINEERED ENZYMES
    Publication number: 20200123517
    Abstract: The present disclosure provides engineered RNA-guided enzymes for editing live cells.
    Type: Application
    Filed: October 21, 2019
    Publication date: April 23, 2020
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Kyle Seamon, Andrew Garst
  • Engineered enzymes
    Patent number: 10604746
    Abstract: The present disclosure provides engineered RNA-guided enzymes for editing live cells.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: March 31, 2020
    Assignee: Inscripta, Inc.
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Kyle Seamon, Andrew Garst
  • COMPOSITIONS AND METHODS FOR IMPROVED GENE EDITING
    Publication number: 20190345479
    Abstract: The disclosure provides novel methods and compositions for gene editing. In particular, the disclosure relates to compositions and methods of making modified nucleic acid donor templates for highly efficient and precise gene editing.
    Type: Application
    Filed: April 15, 2019
    Publication date: November 14, 2019
    Inventors: Craig Cameron Mello, Krishna Sumanth Ghanta, Gregoriy Dokshin, Aamir Mir, Hassan Gneid, Jonathan Kenneth Watts, Erik Joseph Sontheimer
  • Targeted CRISPR Delivery Platforms
    Publication number: 20190338308
    Abstract: The present invention is related to compositions and methods for gene therapy. Several approaches described herein utilize the Neisseria meningitidis Cas9 system that provides a hyperaccurate CRISPR gene editing platform. Furthermore, the invention incorporates full length and truncated single guide RNA sequences that permit a complete sgRNA-Nme1Cas9 vector to be inserted into an adeno-associated viral plasmid that is compatible for in vivo administration. Furthermore, Type II-C Cas9 orthologs have been identified that target protospacer adjacent motif sequences limited to between one-four required nucleotides.
    Type: Application
    Filed: November 9, 2018
    Publication date: November 7, 2019
    Inventors: Erik J. Sontheimer, Raed Ibraheim, Wen Xue, Aamir Mir, Alireza Edraki, Ildar Gainetdinov